Market News AIOpen the app

Erasca Reports Positive Phase 1 Clinical Data for Pan-RAS Molecular Glue ERAS-0015

TrialRead the original at globenewswire.com
Good for ERAS

Erasca's 32 mg dose produced confirmed tumor responses in 44% of this patient group, and the company reported favorable safety. The drug remains in early testing, but these results support a positive read.

ERAS · Erasca, Inc.

AI read · Good for ERAS

The AI's read

These results give Erasca early evidence that the drug may help people with hard-to-treat tumors. Favorable safety adds support. But the drug is still being tested, and the next study has not started.

Get alerts for ERAS

Follow Erasca, Inc. (ERAS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ERAS
Free on the App Store and Google Play, or on the web.